INJECTABLE DRUG DELIVERY MARKET ANALYSIS

Global Injectable Drug Delivery Market – Market Insights

Injectable drug delivery is considered as the most effective route of administration for the effective delivery of drugs to the targeted site, which enhances the patient’s compliance to the drug. The Injectable delivery enhances the rapid absorption of drug from various sites such as subcutaneous, intravenous, and intramuscular. The injectable delivery increases the bioavailability of the drug at the systemic circulation, which offers availability of drug at intended site of action. 

The global injectable drug delivery market size was valued at US$ 15,939.0 million in 2017, and is expected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026).

Figure 1. Global Injectable Drug Delivery Market Value (US$ Mn), by Region, 2017

To learn more about this report, request sample copy

                                                                    Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of chronic diseases such as diabetes and anaphylaxis is expected to propel growth of the global injectable drug delivery market

Increasing prevalence of chronic diseases such as diabetes and other diseases is expected to drive the market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to World Health Organization (WHO) 2018 factsheet, around 8.5% adults aged 18 years and above had diabetes in 2014 globally.

Moreover, the market players are focused on product development and launch of injectors, which is expected to propel growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received the FDA approval.

However, increasing product recalls is expected to hinder the market growth. In December 2012, Bracco Diagnostics Inc., initiated a Class I recall of nine lots of Isovue Pre-Filled Power Injector Syringes, which are to be used with Stellant CT Injection Systems, due to presence of visible particles in syringes observed at the end of standard stability studies on retained samples, according to the U.S. Food and Drug Administration (FDA)

Figure 2. Global Injectable Drug Delivery Market Share (%), by Usability,2018 and 20   

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2019)

Increasing product approval and launch in North America is expected to bolster the market growth

North America holds dominant position in the global injectable drug delivery market, owing to increased focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

Moreover, increasing incidence of chronic diseases such as anaphylaxis, diabetes, and cardiac arrest in the region is expected to support growth of the market during the forecast period. For instance, according to Journal of Allergy and Clinical Immunology, 2014, prevalence of anaphylaxis in the U.S. was 1.6% in the general population, while the number of hospitalizations associated with the disease is ever increasing in the U.S.

Furthermore, increasing initiatives by companies to make auto-injectors available to patients suffering from anaphylaxis is expected to boost global injectable drug delivery market. For instance, Mylan N.V. provides discount cards to epinephrine buyers, and offers discounts up to US$ 300 on branded version of EpiPen and up to US$ 25 on the approved generic version of EpiPen.

Key Players

Major players operating in the global injectable drug delivery market include Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, and Injex Pharma GmbH